sumatriptan has been researched along with Innate Inflammatory Response in 21 studies
Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.
sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To demonstrate that sumatriptan may induce activation or aggravation of pain at sites of inflammation caused by trauma or disease." | 7.72 | Activation of pain by sumatriptan. ( Clark, DW; Coulter, DM; Passier, JL; van Puijenbroek, EP, 2003) |
| " The aim of these studies was to evaluate the effects of the 5-HT(1B/1D) receptor agonist sumatriptan in specific models of pain states: a mouse model of inflammation-induced thermal hyperalgesia and a rat model of nerve injury-induced thermal hyperalgesia." | 7.71 | Inhibition of inflammation-induced thermal hypersensitivity by sumatriptan through activation of 5-HT(1B/1D) receptors. ( Bingham, S; Davey, PT; Overend, P; Parsons, AA; Raval, P; Sammons, M, 2001) |
| "Treatment with sumatriptan significantly increased the endothelial nitric oxide synthase (eNOS) expression consequences nitric oxide metabolites' level in I/R rats." | 5.51 | Sumatriptan protects against myocardial ischaemia-reperfusion injury by inhibition of inflammation in rat model. ( Azizi, Y; Dehpour, AR; Dehpour, S; Faghir-Ghanesefat, H; Ghahremani, MH; Keshavarz-Bahaghighat, H; Rahimi, N; Sepand, MR; Sheibani, M, 2019) |
| "To describe the pharmacokinetic and safety profiles of sumatriptan 85 mg formulated with RT Technology (RT) and naproxen sodium 500 mg in a fixed-dose combination tablet (sumatriptan/naproxen sodium) that targets both serotonergic dysmodulation and inflammation in migraine." | 5.14 | Distinct pharmacokinetic profile and safety of a fixed-dose tablet of sumatriptan and naproxen sodium for the acute treatment of migraine. ( Haberer, LJ; Lener, SE; McDonald, SA; Taylor, DR; Walls, CM, 2010) |
| " Both neurogenic inflammation and c-fos expression are blocked by sumatriptan and ergot alkaloids via prejunctional mechanisms involving putative 5-HT receptors closely related to the 5-HT1D subtype on trigeminovascular fibers." | 4.78 | Neurogenic inflammation in the pathophysiology and treatment of migraine. ( Moskowitz, MA, 1993) |
| "The present study showed that repeated IS stimulations induced long-lasting allodynia, increased BBB permeability, and upregulated VEGF expression, all of which could be attenuated by early sumatriptan treatment." | 3.88 | Recurrent Headache Increases Blood-Brain Barrier Permeability and VEGF Expression in Rats. ( Chen, L; Mi, X; Qin, G; Ran, L, 2018) |
| "To demonstrate that sumatriptan may induce activation or aggravation of pain at sites of inflammation caused by trauma or disease." | 3.72 | Activation of pain by sumatriptan. ( Clark, DW; Coulter, DM; Passier, JL; van Puijenbroek, EP, 2003) |
| " The aim of these studies was to evaluate the effects of the 5-HT(1B/1D) receptor agonist sumatriptan in specific models of pain states: a mouse model of inflammation-induced thermal hyperalgesia and a rat model of nerve injury-induced thermal hyperalgesia." | 3.71 | Inhibition of inflammation-induced thermal hypersensitivity by sumatriptan through activation of 5-HT(1B/1D) receptors. ( Bingham, S; Davey, PT; Overend, P; Parsons, AA; Raval, P; Sammons, M, 2001) |
| "Initiating mechanisms of migraine headache remain poorly understood and a biomarker of migraine does not exist." | 2.90 | Investigating macrophage-mediated inflammation in migraine using ultrasmall superparamagnetic iron oxide-enhanced 3T magnetic resonance imaging. ( Amin, FM; Ashina, M; Birgens, H; Christensen, CE; Daldrup-Link, H; Fliedner, FP; Khan, S; Kjær, A; Larsson, HBW; Lindberg, U; Olinger, ACR; Tolnai, D; Younis, S, 2019) |
| "Current migraine therapy was triptans, however, riptans can cause contraction of blood vessels." | 1.62 | Design, synthesis and biological evaluation of pyridinylmethylenepiperidine derivatives as potent 5-HT ( Chen, K; Deng, K; Jin, C; Wang, T; Wang, Z; Xue, Y; Yi, C; Zhong, W, 2021) |
| "Pre-treatment with sumatriptan decreased 5-hydroxytryptamine (5HT) level by 53%, and significantly decreased calcitonin gene-related peptide (CGRP) levels, lipid pereoxidation, neutrophil infiltration, and level of pro-inflammatory markers in the serum." | 1.56 | Involvement of 5-HT1B/1D receptors in the inflammatory response and oxidative stress in intestinal ischemia/reperfusion in rats. ( Abdollahi, A; Dehpour, AR; Gharishvandi, F; Mohammad Jafari, R; Pasalar, P; Shafaroodi, H, 2020) |
| "Treatment with sumatriptan significantly increased the endothelial nitric oxide synthase (eNOS) expression consequences nitric oxide metabolites' level in I/R rats." | 1.51 | Sumatriptan protects against myocardial ischaemia-reperfusion injury by inhibition of inflammation in rat model. ( Azizi, Y; Dehpour, AR; Dehpour, S; Faghir-Ghanesefat, H; Ghahremani, MH; Keshavarz-Bahaghighat, H; Rahimi, N; Sepand, MR; Sheibani, M, 2019) |
| "Neurogenic dural inflammation has been proposed as a source of pain during migraine." | 1.30 | A fluorescence-based method for assessing dural protein extravasation induced by trigeminal ganglion stimulation. ( Johnson, KW; Phebus, LA, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (28.57) | 18.2507 |
| 2000's | 6 (28.57) | 29.6817 |
| 2010's | 5 (23.81) | 24.3611 |
| 2020's | 4 (19.05) | 2.80 |
| Authors | Studies |
|---|---|
| Ennis, MD | 1 |
| Ghazal, NB | 1 |
| Hoffman, RL | 1 |
| Smith, MW | 1 |
| Schlachter, SK | 1 |
| Lawson, CF | 1 |
| Im, WB | 1 |
| Pregenzer, JF | 1 |
| Svensson, KA | 1 |
| Lewis, RA | 1 |
| Hall, ED | 1 |
| Sutter, DM | 1 |
| Harris, LT | 1 |
| McCall, RB | 1 |
| Xu, YC | 1 |
| Johnson, KW | 2 |
| Phebus, LA | 2 |
| Cohen, M | 1 |
| Nelson, DL | 1 |
| Schenck, K | 1 |
| Walker, CD | 1 |
| Fritz, JE | 1 |
| Kaldor, SW | 1 |
| LeTourneau, ME | 1 |
| Murff, RE | 1 |
| Zgombick, JM | 1 |
| Calligaro, DO | 1 |
| Audia, JE | 1 |
| Schaus, JM | 1 |
| Saunders, MJ | 1 |
| Edwards, BS | 1 |
| Zhu, J | 1 |
| Sklar, LA | 1 |
| Graves, SW | 1 |
| Jin, C | 1 |
| Yi, C | 1 |
| Zhong, W | 1 |
| Xue, Y | 1 |
| Chen, K | 1 |
| Deng, K | 1 |
| Wang, Z | 1 |
| Wang, T | 1 |
| Winters, BL | 1 |
| Jeong, HJ | 1 |
| Vaughan, CW | 1 |
| Gharishvandi, F | 1 |
| Abdollahi, A | 1 |
| Shafaroodi, H | 1 |
| Mohammad Jafari, R | 2 |
| Pasalar, P | 1 |
| Dehpour, AR | 3 |
| Ala, M | 1 |
| Ghasemi, M | 1 |
| Mi, X | 1 |
| Ran, L | 1 |
| Chen, L | 1 |
| Qin, G | 1 |
| Sheibani, M | 1 |
| Faghir-Ghanesefat, H | 1 |
| Dehpour, S | 1 |
| Keshavarz-Bahaghighat, H | 1 |
| Sepand, MR | 1 |
| Ghahremani, MH | 1 |
| Azizi, Y | 1 |
| Rahimi, N | 1 |
| Khan, S | 1 |
| Amin, FM | 1 |
| Fliedner, FP | 1 |
| Christensen, CE | 1 |
| Tolnai, D | 1 |
| Younis, S | 1 |
| Olinger, ACR | 1 |
| Birgens, H | 1 |
| Daldrup-Link, H | 1 |
| Kjær, A | 1 |
| Larsson, HBW | 1 |
| Lindberg, U | 1 |
| Ashina, M | 1 |
| Nikai, T | 1 |
| Basbaum, AI | 1 |
| Ahn, AH | 1 |
| Hoffmann, J | 1 |
| Neeb, L | 1 |
| Israel, H | 1 |
| Dannenberg, F | 1 |
| Triebe, F | 1 |
| Dirnagl, U | 1 |
| Reuter, U | 1 |
| Haberer, LJ | 1 |
| Walls, CM | 1 |
| Lener, SE | 1 |
| Taylor, DR | 1 |
| McDonald, SA | 1 |
| De Salvatore, G | 1 |
| De Salvia, MA | 1 |
| Piepoli, AL | 1 |
| Natale, L | 1 |
| Porro, C | 1 |
| Nacci, C | 1 |
| Mitolo, CI | 1 |
| Mitolo-Chieppa, D | 1 |
| Coulter, DM | 1 |
| Passier, JL | 1 |
| Clark, DW | 1 |
| van Puijenbroek, EP | 1 |
| Moskowitz, MA | 2 |
| Gupta, P | 1 |
| Brown, D | 1 |
| Butler, P | 1 |
| Ellis, P | 1 |
| Grayson, KL | 1 |
| Land, GC | 1 |
| Macor, JE | 1 |
| Robson, SF | 1 |
| Wythes, MJ | 1 |
| Shepperson, NB | 1 |
| Durham, PL | 1 |
| Russo, AF | 1 |
| Bingham, S | 1 |
| Davey, PT | 1 |
| Sammons, M | 1 |
| Raval, P | 1 |
| Overend, P | 1 |
| Parsons, AA | 1 |
| Buzzi, MG | 1 |
| Peroutka, SJ | 1 |
| Byun, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Investigation of Vascular Inflammation in Migraine Without Aura Using Molecular Nano-imaging and Black Blood Imaging MRI[NCT02549898] | 34 participants (Actual) | Interventional | 2015-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for sumatriptan and Innate Inflammatory Response
| Article | Year |
|---|---|
Beyond its anti-migraine properties, sumatriptan is an anti-inflammatory agent: A systematic review.
Topics: Anti-Inflammatory Agents; Humans; Inflammation; Migraine Disorders; Sumatriptan; Tumor Necrosis Fact | 2021 |
Neurogenic inflammation in the pathophysiology and treatment of migraine.
Topics: Blood Proteins; Gene Expression; Genes, fos; Humans; Indoles; Inflammation; Migraine Disorders; Sero | 1993 |
2 trials available for sumatriptan and Innate Inflammatory Response
| Article | Year |
|---|---|
Investigating macrophage-mediated inflammation in migraine using ultrasmall superparamagnetic iron oxide-enhanced 3T magnetic resonance imaging.
Topics: Adult; Animals; Brain; Cilostazol; Dextrans; Female; Humans; Inflammation; Macrophages; Magnetic Res | 2019 |
Distinct pharmacokinetic profile and safety of a fixed-dose tablet of sumatriptan and naproxen sodium for the acute treatment of migraine.
Topics: Acute Disease; Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Biological Avai | 2010 |
17 other studies available for sumatriptan and Innate Inflammatory Response
| Article | Year |
|---|---|
Isochroman-6-carboxamides as highly selective 5-HT1D agonists: potential new treatment for migraine without cardiovascular side effects.
Topics: Animals; Benzopyrans; Biological Availability; Blood Pressure; Brain; Capillary Permeability; Caroti | 1998 |
N-[3-(2-Dimethylaminoethyl)-2-methyl-1H- indol-5-yl]-4-fluorobenzamide: a potent, selective, and orally active 5-HT(1F) receptor agonist potentially useful for migraine therapy.
Topics: Animals; Benzamides; Cell Line; Dura Mater; Guinea Pigs; Humans; In Vitro Techniques; Indoles; Infla | 2001 |
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Pr | 2010 |
Design, synthesis and biological evaluation of pyridinylmethylenepiperidine derivatives as potent 5-HT
Topics: Animals; Body Weight; Dose-Response Relationship, Drug; Drug Design; Eating; Female; Haplorhini; HEK | 2021 |
Inflammation induces developmentally regulated sumatriptan inhibition of spinal synaptic transmission.
Topics: Animals; Inflammation; Posterior Horn Cells; Rats; Rats, Sprague-Dawley; Spinal Cord; Sumatriptan; S | 2020 |
Involvement of 5-HT1B/1D receptors in the inflammatory response and oxidative stress in intestinal ischemia/reperfusion in rats.
Topics: Animals; Calcitonin Gene-Related Peptide; Ileum; Inflammation; Intestinal Mucosa; Male; Mesenteric I | 2020 |
Recurrent Headache Increases Blood-Brain Barrier Permeability and VEGF Expression in Rats.
Topics: Animals; Blood-Brain Barrier; Capillary Permeability; Headache; Hyperalgesia; Inflammation; Male; Mi | 2018 |
Sumatriptan protects against myocardial ischaemia-reperfusion injury by inhibition of inflammation in rat model.
Topics: Animals; Cardiotonic Agents; Inflammation; Lipid Peroxidation; Male; Myocardial Reperfusion Injury; | 2019 |
Profound reduction of somatic and visceral pain in mice by intrathecal administration of the anti-migraine drug, sumatriptan.
Topics: Acetic Acid; Analgesics, Non-Narcotic; Animals; Blood-Brain Barrier; Carrageenan; Drug Evaluation, P | 2008 |
Intracisternal injection of inflammatory soup activates the trigeminal nerve system.
Topics: Animals; Bradykinin; Calcitonin Gene-Related Peptide; Dinoprostone; Fructose; Histamine; Histamine A | 2009 |
Effects of in vivo treatment with interleukins 1beta and 6 on rat mesenteric vascular bed reactivity.
Topics: Acetylcholine; Animals; Arginine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Syn | 2003 |
Activation of pain by sumatriptan.
Topics: Adult; Female; Humans; Inflammation; Injections, Subcutaneous; Male; Middle Aged; Pain; Prospective | 2003 |
The in vivo pharmacological profile of a 5-HT1 receptor agonist, CP-122,288, a selective inhibitor of neurogenic inflammation.
Topics: Anesthesia; Animals; Anti-Inflammatory Agents, Non-Steroidal; Capillary Permeability; Dogs; Dose-Res | 1995 |
A fluorescence-based method for assessing dural protein extravasation induced by trigeminal ganglion stimulation.
Topics: Animals; Biological Transport; Dura Mater; Electric Stimulation; Evans Blue; Extravasation of Diagno | 1998 |
Regulation of calcitonin gene-related peptide secretion by a serotonergic antimigraine drug.
Topics: Animals; Animals, Newborn; Calcitonin Gene-Related Peptide; Cells, Cultured; Colforsin; Cyclic AMP; | 1999 |
Inhibition of inflammation-induced thermal hypersensitivity by sumatriptan through activation of 5-HT(1B/1D) receptors.
Topics: Analysis of Variance; Animals; Carrageenan; Discriminant Analysis; Disease Models, Animal; Female; H | 2001 |
Further characterization of the putative 5-HT receptor which mediates blockade of neurogenic plasma extravasation in rat dura mater.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Blood Pressure; Blood Proteins; Conjunctiva; Dura M | 1991 |